KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesLong-Term Debt IssuancesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares Repurchased
Ratios

Labcorp Holdings (LH) EBIAT (2016 - 2025)

Labcorp Holdings (LH) has disclosed EBIAT for 17 consecutive years, with $164.7 million as the latest value for Q4 2025.

  • Quarterly EBIAT rose 14.69% to $164.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $876.5 million through Dec 2025, up 17.41% year-over-year, with the annual reading at $876.5 million for FY2025, 17.32% up from the prior year.
  • EBIAT hit $164.7 million in Q4 2025 for Labcorp Holdings, down from $261.1 million in the prior quarter.
  • In the past five years, EBIAT ranged from a high of $769.6 million in Q1 2021 to a low of -$128.0 million in Q4 2023.
  • Historically, EBIAT has averaged $287.0 million across 5 years, with a median of $220.4 million in 2023.
  • Biggest five-year swings in EBIAT: surged 342.62% in 2021 and later tumbled 264.95% in 2023.
  • Year by year, EBIAT stood at $553.6 million in 2021, then plummeted by 85.98% to $77.6 million in 2022, then crashed by 264.95% to -$128.0 million in 2023, then skyrocketed by 212.19% to $143.6 million in 2024, then increased by 14.69% to $164.7 million in 2025.
  • Business Quant data shows EBIAT for LH at $164.7 million in Q4 2025, $261.1 million in Q3 2025, and $237.9 million in Q2 2025.